Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 4: 642 - 651

DOI: https://doi.org/10.19852/j.cnki.jtcm.2024.04.006

Original articles

Saponin Ⅰ from Shuitianqi (Rhizoma Schizocapasae Plantagineae) inhibits metastasis by negatively regulating the transforming growth factor-β1/Smad7 network and epithelial-mesenchymal transition in the intrahepatic metastasis Bagg’s Albino/c mouse model

  • Meixian LYU ,
  • Huan ZHOU ,
  • Limin ZHI ,
  • Jinling ZHOU ,
  • Rizhi GAN ,
  • Yanping QIN ,
  • Nengting HE ,
  • Qiqi ZUO ,
  • Hao LI ,
  • Min DONG ,
  • Gang LIANG
Expand
  • 1 Pharmaceutical College, Guangxi Medical University, Nanning 530022, China
    2 Department of Pharmacy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530022, China
    3 Drug clinical trial Facility office, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530022, China
    4 College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530022, China
    5 Department of Pharmacy, the Second Affiliated Hospital of Guangxi Medical University, Nanning 530005, China
    6 Department of Pharmacy, People’s Hospital of Guangxi Hezhou, Hezhou 542899, China
    7 Department of Pharmacy, Guangzhou Women and Children’s Medical Center Liuzhou Hospital, Liuzhou 545000, China
    8 Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Gannan 341000, China

Received date: 2023-03-21

  Accepted date: 2023-08-29

  Online published: 2024-07-15

Supported by

National Natural Science Foundation of China, a New Anti-cancer Plant drug, Saponin Ⅰ from Shuitianqi (Rhizoma Schizocapasae Plantagineae), against Invasion and Metastasis of Non-small Cell Lung Cancer and Reversing Tyrosine Kinase Inhibitors Resistance basing on Human Growth Factor/c-Mesenchymal to Epithelial Transition Factor Pathway and its Molecular Mechanism of Regulating Epithelial-Mesenchymal Transition(8164062);Natural Science Foundation of Guangxi Province, Study on the Anti-hepatic Fibrosis Mechanism of Saponins from Shuitianqi (Rhizoma Schizocapasae Plantagineae) based on Transforming Growth Factor-β/Smad Signaling Pathway(2019GXNSFAA245075)

Fold

Abstract

OBJECTIVE: To examine the influence of Saponin I from Shuitianqi (Rhizoma Schizocapasae Plantagineae) (SSPH I) on hepatocellular carcinoma (HCC) metastasis, and to elucidate the underlying mechanism.

METHODS: The intrahepatic metastasis Bagg’s Albino/c (BALB/c) mouse model was established with human hepatocellular carcinomas (HepG2) cells, then treated with normal saline (once per day), cisplatin (2 mg/kg, once every 2 d), and SSPH Ⅰ (25, 50, and 75 mg/kg, once per day). Then, we assessed alterations in the hepatic pathology and target protein expressions in the intrahepatic metastasis BALB/c mouse model using a series of molecular biology techniques.

RESULTS: Based on our analysis, SSPH Ⅰ significantly alleviated hepatocyte necrosis and tumor cells infiltration. Moreover, SSPH Ⅰ suppressed extracellular matrix (ECM) degradation and angiogenesis viaa decrease in matrix etalloproteinase-2 (MMP-2), MMP-9, CD31, CD34, and vascular endothelial growth factor (VEGF) levels. Furthermore, SSPH Ⅰ repressed invasion and meta-stasis by suppressing the transforming growth factor-β1 (TGF-β1)/Smad7 axis and epithelial-mesenchymal transition (EMT), as evidenced by the scarce TGF-β1, N-cadherin, and Vimentin expressions, and elevated Smad7 and E-cadherin expressions.

CONCLUSION: The SSPH Ⅰ-mediated negative regulation of the TGF-β1/Smad7 axis and EMT are critical for the inhibition of HCC invasion and metastasis.

Key words： carcinoma, hepatocellular; epithelial-mesenchymal transition; transforming growth factor beta1; Smad7 protein; Saponin I from Shuitianqi (Rhizoma Schizocapasae Plantagineae)

Cite this article

Meixian LYU , Huan ZHOU , Limin ZHI , Jinling ZHOU , Rizhi GAN , Yanping QIN , Nengting HE , Qiqi ZUO , Hao LI , Min DONG , Gang LIANG . Saponin Ⅰ from Shuitianqi (Rhizoma Schizocapasae Plantagineae) inhibits metastasis by negatively regulating the transforming growth factor-β1/Smad7 network and epithelial-mesenchymal transition in the intrahepatic metastasis Bagg’s Albino/c mouse model[J]. Journal of Traditional Chinese Medicine, 2024 , 44(4) : 642 -651 . DOI: 10.19852/j.cnki.jtcm.2024.04.006

References

1. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res 2021; 149: 1-61.
2. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019; 156: 477-91.e1.
3. Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 2010; 3: 55-66.
4. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818-29.
5. Gurzu S, Kobori L, Fodor D, Jung I. Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: a review. Biomed Res Int 2019; 2019: 2962580.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
8. Shrestha R, Prithviraj P, Bridle KR, Crawford DHG, Jayachandran A. Combined inhibition of TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular carcinoma to sorafenib treatment. J Clin Med 2021; 10: 1889.
9. Chen Z, Xiang L, Li L, et al. TGF-β1 induced deficiency of linc00261 promotes epithelial-mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3. J Transl Med 2022; 20: 75.
10. Gurzu S, Silveanu C, Fetyko A, Butiurca V, Kovacs Z, Jung I. Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer. World J Gastroenterol 2016; 22: 6764-75.
11. Lin YT, Wu KJ. Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-β signaling. J Biomed Sci 2020; 27: 39.
12. Heldin CH, Landstr?m M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-76.
13. Sui H, Zhao J, Zhou L, et al. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer. Cancer Lett 2017; 403: 86-97.
14. Fina L, Molgaard HV, Robertson D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417-26.
15. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752-7.
16. Pisacane AM, Picciotto F, Risio M. CD31 and CD34 expression as immunohistochemical markers of endothelial trans-differentiation in human cutaneous melanoma. Cell Oncol 2007; 29: 59-66.
17. Itoh Y, Nagase H. Matrix metalloproteinases in cancer. Essays Biochem 2002; 38: 21-36.
18. Niland S, Riscanevo AX, Eble JA. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int J Mol Sci 2021; 23: 146.
19. Wen Y, Cai X, Chen S, et al. 7-Methoxy-1-tetralone induces apoptosis, suppresses cell proliferation and migration in hepatocellular carcinoma via regulating c-Met, p-AKT, NF-κB, MMP2, and MMP9 expression. Front Oncol 2020; 10: 58.
20. Jiang L, Xie X, Bi R, Ding F, Mei J. Knockdown of Linc00511 inhibits TGF-β-induced cell migration and invasion by suppressing epithelial-mesenchymal transition and down-regulating MMPs expression. Biomed Pharmacother 2020; 125: 109049.
21. Li JJ, Liang Q, Sun GC. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition. J Integr Med 2021; 19: 469-77.
22. Chen J, Bian XL, Zhu FY, Liu L, Zhu YD. Investigation on Traditional Chinese Medicine syndrome elements and symptom distribution of liver cancer. Zhong Yi Zhong Liu Xue Za Zhi 2022; 4: 47-50.
23. Sun YW, Qiu HC, Ou MC, Chen RL, Liang G. Saponins isolated from Schizocapsa plantaginea inhibit human hepatocellular carcinoma cell growth in vivo and in vitro via mitogen-activated protein kinase signaling. Chin J Nat Med 2018; 16: 29-40.
24. Zhou JL, Huang XY, Qiu HC, et al. SSPH I, a novel anti-cancer saponin, inhibits autophagy and induces apoptosis via ROS accumulation and ERK1/2 signaling pathway in hepatocellular carcinoma cells. Onco Targets Ther 2020; 13: 5979-91.
25. Zhao YZ, Zhang YY, Han H, et al. Advances in the antitumor activities and mechanisms of action of steroidal saponins. Chin J Nat Med 2018; 16: 732-48.
26. Liu P, Xu DW, Li RT, et al. A combined phytochemistry and network pharmacology approach to reveal potential anti-NSCLC effective substances and mechanisms in marsdenia tenacissima (Roxb.) moon (Stem). Front Pharmacol 2021; 12: 518406.
27. Zhang S, Lu Y, Li H, et al. A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway. Biosci Trends 2020; 14: 123-33.
28. Scheau C, Badarau IA, Costache R, et al. The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma. Anal Cell Pathol (Amst) 2019; 2019: 9423907.
29. Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. J Clin Med 2016; 5:17.
30. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol 2019; 29: 212-26.
31. Liao S, Chen H, Liu M, et al. Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/β-catenin pathway. Aging (Albany NY) 2020; 12: 1527-44.
32. Jiang Y, Han Q, Zhao H, Zhang J. Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b/β-catenin/c-Myc signaling and reprogramming glycolysis. J Exp Clin Cancer Res 2021; 40: 13.
33. Meng W, Chen T. Association between the HGF/c?MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (review). Oncol Rep 2021; 46: 191.
Options
Outlines

/

〈 〉